Article
MEK inhibition may increase survival of NRAS-mutated melanoma patients treated with checkpoint blockade: Results of a retrospective multicentre analysis of 364 patients.
European journal of cancer (Oxford, England : 1990) - 1 Jul 2018
Kirchberger Michael Constantin, Ugurel Selma, Mangana Johanna, Heppt Markus Valentin, Eigentler Thomas Kurt, Berking Carola, Schadendorf Dirk, Schuler Gerold, Dummer Reinhard, Heinzerling Lucie
Abstract excerpt
BACKGROUND: Melanoma harbours genetic alterations in genes such as BRAF, NRAS and KIT. Activating NRAS mutations are present in about 20% of melanomas. Even though BRAF mutations can be effectively targeted with specific inhibitors, this approach has proven more challenging in cases of NRAS mutations. Previous reports suggested that immunotherapy might be more successful in NRAS-mutated compared to BRAF-mutated...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.